Akari Therapeutics PLC

Akari Therapeutics Plc held its Annual General Meeting on June 30, 2026, where shareholders voted on various resolutions, including the re-election of directors and auditor ratification.

Akari Therapeutics has amended its securities purchase agreement to consolidate the second and third tranches of its private placement into a single closing on June 26, 2026.

Akari Therapeutics has entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a private placement of units.

Akari Therapeutics will implement a 1-for-40 reverse split of its American Depositary Shares to meet Nasdaq's minimum bid price requirement.

Akari Therapeutics shareholders approved the exercisability of warrants covering over 44 million American Depositary Shares, enabling the issuance of underlying ordinary shares.

Akari Therapeutics announced a $9 million financing package, combining a $5 million equity raise with a $4 million debt-to-equity conversion, to fund R&D and improve its capital structure.

Akari Therapeutics reports a substantial increase in net loss for Q1 2026, driven by significant non-cash impairment charges on goodwill and intangible assets, while cash reserves dwindle.

Akari Therapeutics reported substantial losses and a going concern warning for Q3 2025, despite a strategic shift to its ADC platform and recent capital raises.

Akari Therapeutics reported a significantly reduced net loss in the first half of 2025, driven by strategic pipeline prioritization, but continues to face substantial doubt about its ability to continue as a going concern without further financing.

Akari Therapeutics reports a net loss of $3.7 million for Q1 2025, shifting focus to its antibody-drug conjugate (ADC) platform and pipeline.

Akari Therapeutics reports a net loss of $16 million for the nine months ended September 30, 2024, and announces the completion of its merger with Peak Bio, along with a strategic pipeline prioritization.

Akari Therapeutics reported its second quarter 2024 results, highlighting a strategic shift towards a merger with Peak Bio and a focus on its PAS-nomacopan program for geographic atrophy.

Akari Therapeutics shifts focus to oncology with its ADC platform following a merger, while acknowledging significant financial risks and material weaknesses in internal controls in its recent 10-K filing.

Akari Therapeutics, Plc details the rights and characteristics of its ordinary shares and American Depositary Shares (ADSs) in a recent SEC filing.

Samir Rashmikant Patel, a Director and 10% owner of Akari Therapeutics Plc, reported multiple transactions in common stock on July 7, 2026.

Kameel D. Farag, Interim CFO of Akari Therapeutics Plc, reported transactions involving the acquisition of American Depositary Shares.

Akari Therapeutics Plc reports a Form 4 filing detailing stock option transactions by CEO Abizer Gaslightwala.

Akari Therapeutics Director James R. Neal acquired various warrants to purchase American Depositary Shares through a private placement and a debt-for-equity exchange.

Akari Therapeutics Director Raymond Prudo-Chlebosz acquired over 2 million derivative securities, including warrants and pre-funded warrants, through a private placement and a note exchange agreement.

Akari Therapeutics director Sandip Patel acquired warrants and pre-funded warrants, including some through a private placement and others by converting an outstanding promissory note.

Akari Therapeutics, Plc is seeking shareholder approval for the exercisability of warrants issued in recent offerings and a note exchange to comply with Nasdaq listing rules.

Akari Therapeutics calls a General Meeting to approve warrant exercisability and a comprehensive capital restructuring, including a share sub-division and new share allotment authority.

Akari Therapeutics, Plc is seeking shareholder approval for a significant increase in its equity incentive plan, new share allotment authority, and director stock options, as the company reports a 32% decrease in cash and a near doubling of net losses for the fiscal year ended December 31, 2024.

Akari Therapeutics, Plc will hold its 2024 Annual General Meeting of Shareholders on June 27, 2024, in London.

Akari Therapeutics registers up to 2.5 million ADSs for potential resale by White Lion Capital under a $25 million purchase agreement.

Akari Therapeutics, PLC has filed a registration statement for a best-efforts offering of ADSs and warrants to raise approximately $7.5 million for research and development.

Akari Therapeutics, an oncology company, is shifting its focus to next-generation antibody-drug conjugates (ADCs) following a recent merger, but faces significant financial challenges and a Nasdaq delisting threat.

Akari Therapeutics filed an S-1 registration statement for the resale of 6.375 million ADSs by selling shareholders, stemming from recent warrant issuances.

Akari Therapeutics has entered into an agreement with White Lion Capital for an equity line of up to $25 million, providing discretionary capital access over the next three years.

Dr. Ray Prudo and affiliated entities have increased their beneficial ownership in Akari Therapeutics Plc to 8.9% following recent private placement transactions.

Samir R. Patel and PranaBio Investments LLC have increased their beneficial ownership in Akari Therapeutics Plc to 10.4% following a private placement.

Dr. Ray Prudo, a key reporting person, has increased his beneficial ownership in Akari Therapeutics, Plc to 9.3% of outstanding Ordinary Shares following participation in a December 2024 private placement.

MMCAP International Inc. SPC and MM Asset Management Inc. have reported an 8% beneficial ownership stake in Akari Therapeutics, Plc.

Dr. Hoyoung Huh has reported beneficial ownership of 18.4% of Akari Therapeutics Plc's ordinary shares, including options and warrants.

Dr. Hoyoung Huh has reported a significant beneficial ownership of 15.5% in Akari Therapeutics, Plc, comprising over 8.29 billion ordinary shares.